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Abstract Rheumatoid arthritis (RA) is a debilitating auto-
immune disease that has traditionally been treated with
disease-modifying anti-rheumatic drugs (DMARDs). In the
European Union (EU), patients who fail to respond to
traditional DMARDs may receive tumor necrosis factor-α
(TNF-α) antagonists. However, approximately one-third of
patients fail TNF-α antagonists due to adverse effects or lack
of efficacy, and there are limited treatment options available
to these patients. As knowledge of the underlying immuno-
pathology of RA evolves, new strategies for inhibiting the
inflammatory process have emerged. It is well known that
activated T cells play a key role in orchestrating the
immunopathological mechanisms of RA. Inhibiting the full
activation of T cells is a rational strategy in the treatment of
RA and represents a novel method of inhibiting disease
activity, distinct from inflammatory cytokine blockade.
Here, the safety and efficacy of abatacept, a selective T-cell
co-stimulation modulator recently approved in the EU, is
reviewed in patients with RAwho have shown an inadequate
response to TNF-α antagonists. In a randomized, placebo-
controlled, double-blind, phase III trial of patients with an
inadequate response to TNF-α antagonism, abatacept was
effective in improving the signs and symptoms of RA, as
well as patient-centered outcomes, such as fatigue, disability,
and other mental and physical aspects of health-related
quality of life. These improvements were sustained through
2 years during the open-label, long-term extension period. In
this trial, abatacept demonstrated a safety and tolerability
profile similar to placebo. Taken together, these data suggest
that selective co-stimulation modulation with abatacept may
be a viable option for patients who are refractory to both
traditional therapies and TNF-α antagonists.
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Introduction
For many adult patients with moderate or severe rheumatoid
arthritis (RA) who are refractory to traditional non-biological
disease-modifying anti-rheumatic drugs (DMARDs), the
advent of the tumor necrosis factor (TNF)-α antagonists
has provided much needed improvement in the clinical signs
and symptoms of disease, as well as in patient-reported
outcomes. However, experience from clinical practice has
shown that not all of these difficult-to-treat patients benefit
from TNF-α blockade; around one-third of patients either
fail to respond to TNF-α antagonists [1] or discontinue
therapy due to adverse effects [2]. As long as there are
patients failing all current treatment options for RA, there is
a need for new therapies, particularly ones with innovative
mechanisms of action.
Abatacept (ORENCIA®, Bristol-Myers Squibb, Princeton,
NJ, USA) is the first in a new class of agents to be made
available in Europe for use in patients with an inadequate
response to TNF-α antagonists [3]. It is a soluble human
fusion protein that selectively modulates T-cell activation
without depleting T cells; it was approved in the European
Union in May 2007 for the treatment of patients with
moderate-to-severe RA who have had an inadequate
response to, or intolerance of, other DMARDs, including at
least one TNF-α antagonist.
This review provides an overview of RA and potential
therapies before examining the rationale for modulating
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T-cell activation with abatacept. Evidence that supports
the use of abatacept in TNF-α antagonist inadequate
responders who have moderate-to-severe RA despite
having had at least 3 months of treatment with a TNF-
α antagonist will then be discussed.
Overview of RA and potential therapeutic options
RA is a chronic, inflammatory disorder that affects between
0.5% and 1.0% of adult women and between 0.1% and
0.6% of adult men in the European Union [4]. It is a multi-
system disease with signs and symptoms that include joint
swelling, pain, prolonged morning joint stiffness, fatigue,
muscle atrophy, and joint erosions [5, 6]. The disease is
usually polyarticular, with bilaterally symmetrical joint
damage [7]. Extra-articular manifestations are common,
including involvement of the eyes (sicca symptoms), lungs
(pleural effusions, interstitial lung disease, nodules), skin
(nodules, ulcers), heart (pericardial effusion, ischemic heart
disease), and hematological system (anemia, thrombo-
cytosis) [8–11]. The onset of symptoms predominantly
occurs in patients over 50 years of age; however, there is a
proclivity for women of child-bearing age [12]. The
progressive pain and destruction of joints leads to increased
disability and a significant impact on lifestyle, including an
inability to work. RA is also associated with premature
mortality, often from co-morbidities, such as cardiovascular
and respiratory disease [11].
The traditional therapeutic pyramid for RA encouraged a
cautious approach to treatment, initially involving non-
steroidal anti-inflammatory drugs (NSAIDs); low doses of
DMARDs, such as methotrexate (MTX), sulfasalazine
(SSZ), and hydroxychloroquine (HCQ); and corticosteroids,
to attempt to reduce inflammation and slow the progression
of disease [13]. However, the management of RA has
changed markedly over the last decade. There has been a
shift to more intensive treatment, including the early use of
non-biologic DMARDs, prescribed alone or in combination
with other non-biologic DMARDs. Latterly, if these
therapies fail, biologic DMARDs have been used to attempt
to improve outcome. Tumor necrosis factor-α antagonists
are one such class of biologic DMARDs, including
etanercept (ENBREL®; Amgen, Thousand Oaks, CA,
USA), infliximab (REMICADE®; Centocor, Malvern, PA,
USA) and adalimumab (HUMIRA®; Abbott Laboratories,
Chicago, IL, USA). These agents have provided a valuable
treatment option for patients with an inadequate response
to, or an inability to tolerate, traditional non-biologic
DMARDs.
Data have shown that patients who fail to respond to their
first TNF-α antagonist may show an adequate response to a
second TNF-α antagonist [2, 14–17]; however, evidence
suggests that the probability of discontinuing therapy with a
second TNF-α antagonist is higher than that of discon-
tinuing the first [18]. Furthermore, retrospective clinical
analysis has predicted that for patients who have failed two
TNF-α antagonists, a third TNF-α antagonist is also likely
to fail [1]. As there are currently no large, randomized
clinical trials that have assessed switching between TNF-α
antagonists, the benefits, or indeed limitations, of switching
remain unclear.
Beyond cycling TNF-α antagonists, one option for this
recalcitrant population would be to return to a non-biologic
DMARD, such as MTX, SSZ, or HCQ, with or without the
use of NSAIDs and corticosteroids; however, this approach
is suboptimal for patients who have had an inadequate
response to non-biologic DMARDs or for those who have
specific co-morbidities.
Until recently, no treatment was available that had a
mechanism of action (MoA) distinct from that of the TNF-α
antagonists. However, there are now two available therapies,
both of which target the underlying immunopathology of RA
in a manner that differs from the TNF-α antagonists.
Abatacept selectively modulates T-cell activation, whereas
rituximab (MabThera®, Hoffmann-La Roche) is a genetical-
ly engineered, chimeric, murine–human anti-CD20 mono-
clonal antibody, which depletes CD20-positive B cells by
several proposed mechanisms [19–21]. Rituximab was
approved in the EU in July 2006 for the treatment of
patients with refractory RA, although it has been approved
for some time for the treatment of non-Hodgkin’s lym-
phoma. Both B-cell depletion with rituximab and T-cell
modulation with abatacept provide therapeutic opportuni-
ties for patients with RA refractory to TNF-α blockade.
The rationale for modulating T-cell activation in RA
RA is an autoinflammatory disease involving multiple cell
types, including dendritic cells, macrophages, monocytes, T
and B cells, endothelial cells, and fibroblasts, which respond
to genetic and environmental factors [22]. Although the
etiology of RA remains obscure, it is thought that an
unknown antigen triggers a pro-inflammatory signaling
cascade within the synovium [22]. Activated T cells play a
central role in this pathway by initiating this cascade with
subsequent stimulation of macrophages and synovial
fibroblasts to produce inflammatory cytokines, including
TNF-α, interleukin-2, and interferon-γ [22]. T cells are
also involved in activating B cells, which then produce
autoantibodies, such as rheumatoid factor and anti-cyclic
citrullinated peptides [23, 24]. In addition, activated T cells
produce the receptor activator of nuclear factor-κB (RANK)
ligand that, in turn, binds to RANK on osteoclasts. This
induces bone resorption and also stimulates chondrocytes to
1344 Clin Rheumatol (2008) 27:1343–1353
produce matrix metalloproteinases-1 and -3, leading to
cartilage destruction [25]. By preventing full T-cell activa-
tion, many of these downstream events leading to joint
destruction may be inhibited.
Abatacept: a selective T-cell co-stimulation modulator
By targeting T cells, abatacept has a fundamentally different
MoA to other therapies for RA. However, rather than
depleting T cells, abatacept modulates T-cell activation by
binding to CD80 and CD86, thereby blocking interaction
with CD28. For full activation, T cells require two distinct
signals, the first occurring when major histocompatibility
complex molecules on antigen-presenting cells (APCs)
[26] present a peptide to the T-cell receptor. The second
(co-stimulatory) signal is provided by further interaction
between specific receptors on the APC and the T cell. If
only one of the signals is transmitted, full activation of T
cells does not occur; this is crucial to the MoA of abatacept.
Abatacept was developed to mimic the action of an
endogenous protein, cytotoxic T-lymphocyte-associated
antigen-4 (CTLA-4) [3], which also binds to CD80/CD86.
CTLA-4 is a transmembrane protein expressed by activated
T cells, which acts as a negative regulator of T-cell
activation; it binds to CD80/CD86 with higher avidity than
CD28, thereby inhibiting the positive co-stimulatory signal
(Fig. 1a). As well as preventing this positive co-stimulation,
the intracellular domain of endogenous CTLA-4 provides a
negative co-stimulatory signal, suppressing further T-cell
activation thus preventing the formation of subsequent
components of the inflammatory cascade [3].
Fig. 1 Rationale for a T-cell
co-stimulation modulator.
a T-cell activation through the
CD28:CD80/CD86 positive
co-stimulatory pathway. In the
normal immune response,
CTLA-4 competes for CD28
binding to CD80/86 and produ-
ces a negative signal causing
downregulation of T-cell activa-
tion. b Structure of abatacept,
a T-cell co-stimulation modula-
tor. Abatacept is a soluble
recombinant fusion protein that
consists of the extracellular
domain of human CTLA-4 and a
modified Fc domain from a




immunoglobulin G, MHC major
histocompatibility complex,
TCR T-cell receptor [Repro-
duced with permission from
Barr C (2007) A Nursing Guide
to Infusion Therapy with
Abatacept for the Treatment of
Rheumatoid Arthritis. Journal of
Infusion Nursing 30(2):96–104]
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Abatacept is a fully soluble human fusion protein,
incorporating only the extracellular domain of human
CTLA-4, which is then linked to a modified Fc portion of
human immunoglobulin G1 [3] (Fig. 1b). The modified Fc
region helps stabilize the fusion protein, but is not
therapeutically active; therefore, abatacept does not mediate
complement-dependent cytotoxicity or antibody-dependent
cell-mediated cytotoxicity (ADCC) [27]. These latter
effects (complement-dependent cytotoxicity and ADCC)
lead to cell lysis, which has been linked to adverse events
(AEs), such as serious infusion reactions [27].
In relation to its unique MoA—selectively modulating
T-cell co-stimulation—abatacept results in decreased pro-
inflammatory cytokine secretion and decreased autoanti-
body production [28], thereby making T-cell co-stimulation
modulation a rational strategy for RA therapy.
Clinical overview of abatacept in patients with RA
refractory to TNF-α antagonists
Abatacept has been shown to reduce disease activity and
improve quality of life (QoL) in this difficult-to-treat patient
population [29, 30]. T-cell modulation with abatacept was
evaluated in patients with moderate to severely active RA
who had failed at least 3 months of TNF-α antagonist
therapy in the ATTAIN (Abatacept Trial in Treatment of
Anti-TNF INadequate responders) trial [29]. In this trial,
258 patients were randomized to abatacept and 133 patients
to placebo, with both being administered by intravenous
infusion. All patients in the trial received background
DMARD therapy: of these 75.6% of patients randomized to
the abatacept group and 82.0% of patients randomized to the
placebo group were receiving backgroundMTX. The patients
who took part in the trial had long-standing, severe RA (mean
disease duration ± standard deviation 12.2±8.5 years for the
abatacept group and 11.4±8.9 years for the placebo group).
Both groups had a high number of tender and swollen joints at
baseline with a mean of 31.2±13.0 tender joints and 22.3±
10.2 swollen joints in the abatacept group, and 32.8±13.4
tender joints and 22.0±10.0 swollen joints in the placebo
group. Evaluation continued during a long-term extension
(LTE) period, where all continuing patients received open-
label abatacept [30]. A total of 218 (84.5%) patients
originally randomized to abatacept and 99 (74.4%) patients
originally randomized to placebo entered the LTE, and 222
(70.0%) of these completed a further 18 months of treatment.
Efficacy with abatacept
The American College of Rheumatology (ACR) response
criteria were used to assess clinical efficacy [31]. The
proportion of abatacept-treated patients who achieved an
ACR 20 response progressively increased over the 6-month
double-blind period and was significantly greater than the
proportion of placebo-treated patients achieving an ACR 20
at all time points. The significant improvement seen with
abatacept over placebo was observed as early as day 15, after
only one dose (Fig. 2a). At 1 month, over 40% of patients
receiving abatacept had achieved an ACR 20 response
compared with less than 20% of placebo-treated patients.
Following 6 months of treatment, 50.4% of abatacept-treated
patients had achieved an ACR 20 response, compared with
19.5% in the placebo group ( p<0.001; Fig. 2b). The
difference between abatacept versus placebo in ACR 50 and
70 response rates was also significant after 6 months, with
20.3% and 10.2% of abatacept-treated patients attaining an
ACR 50 or 70 response, respectively, versus 3.8% and 1.5%
of the placebo-treated patients, respectively ( p<0.001 and
p=0.003 for ACR 50 and ACR 70, respectively; Fig. 2b).
The improvements in signs and symptoms observed at
6 months were maintained through 2 years in patients
originally randomized to abatacept [30]. Using an intent-to-
treat (ITT) analysis that included patients who discontinued
(defined as non-responders) at 2 years, ACR 20, 50, and 70
response rates were 56.2%, 33.2%, and 16.1%, respectively.
Patients who were originally randomized to placebo and
switched to abatacept at the beginning of the LTE period
achieved improvements comparable to those of the patients
originally in the abatacept group at 2 years (using non-
responder analysis, ACR 20, 50, and 70 responses for patients
originally in the placebo group were 51.5%, 32.3%, and
13.1%, respectively). A post hoc analysis was also carried out
on the ITT population using as-observed data; this analysis
showed sustained improvements in ACR responses for the
patients originally randomized to abatacept through 2 years
(Fig. 2c). For ACR 20 and 50, the 95% confidence intervals
(CIs) do no overlap at 6 months and 2 years, suggesting that
there was an improved response over time. The post hoc
analysis may be more relevant over the long term as it follows
only those patients who continue therapy in the study.
Disease activity was also assessed in this trial using the
Disease Activity Score 28 (DAS28). At baseline, these
patients had severe disease, with a DAS28 score of 6.5±0.9
in the abatacept group and 6.5±0.8 in the placebo group
[29]. Following 6 months of treatment, 17.1% of patients
in the abatacept group had low disease activity (LDAS;
defined as a DAS28 score of ≤3.2) after 6 months
compared with 3.1% of patients in the placebo group ( p<
0.001; Fig. 3a) [29]. In addition, 10% of abatacept-treated
patients were in disease remission (defined by a DAS28
[CRP] <2.6), compared with 0.8% of placebo-treated
patients ( p<0.001; Fig. 3a). At 2 years, using the post
hoc as-observed analyses, nearly one-fifth of patients
originally randomized to receive abatacept achieved DAS28
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Fig. 2 ATTAIN phase III trial:
American College of Rheuma-
tology response rates during the
double-blind and long-term
extension periods [29, 30].
a ACR 20 response rate at each
post-baseline visit during the
6-month trial (double-blind
period). The numbers below the
panel are the numbers of
patients with a response who
were assessed. b ACR 20, ACR
50, and ACR 70 responses at
6 months (double-blind period).
Two patients in the abatacept
group were excluded from the
efficacy analysis at 6 months
because of a protocol violation.
c ACR 20, ACR 50, and ACR
70 response rates using a post
hoc as-observed analysis of
patients originally randomized
to abatacept at the beginning of
the 6-month double-blind period
and continued receiving
abatacept during the 18-month
LTE. ACR American College of
Rheumatology, LTE long-term
extension [Genovese MC,
Becker JC, Schiff M et al.
(2005). Abatacept for rheuma-
toid arthritis refractory to tumor
necrosis factor alpha inhibition.
N Engl J Med 353:1114–1123.
Copyright © 2005 Massachu-
setts Medical Society. All rights
reserved; Genovese MC, Schiff
M, Luggen M et al. (2007)
Efficacy and safety of the selec-
tive co-stimulation modulator
abatacept following 2 years of
treatment in patients with rheu-
matoid arthritis and an inade-
quate response to anti-TNF
therapy. Ann Rheum Dis
67:547–554. Reproduced with
permission from the BMJ Pub-
lishing Group]
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(CRP)-defined remission, showing that the proportion of
patients in remission was maintained through the 2 years
(Fig. 3b) [30]. The proportion of patients who achieved
LDAS increased from 18.3% (95% CI; 13.0, 23.5) at the
end of the double-blind period to 32.0% (24.6, 39.4) at
2 years with no overlap in the 95% CIs between 6 months
and 2 years (Fig. 3b).
Improvements in physical function and health-related
quality of life with abatacept
T-cell co-stimulation modulation has been shown to provide
clinically meaningful and statistically significant improve-
ments in multiple aspects of QoL, including mental and
physical function [5, 29]. Improvements in measures such
as fatigue and sleep quality have also been observed in
Fig. 3 ATTAIN phase III trial: the proportion of patients experiencing
disease remission and low disease activity during the double-blind and
long-term extension periods [29, 30]. a DAS28 (CRP)-defined
remission (DAS [CRP] <2.6) and LDAS (DAS [CRP] ≤3.2) at
6 months (double-blind period). Two patients in the abatacept group
were excluded from the efficacy analysis at 6 months because of a
protocol violation. b DAS28 (CRP)-defined remission and LDAS
through 2 years using post hoc as-observed analysis of patients
originally randomized to abatacept at the beginning of the 6-month
double-blind period and continued receiving abatacept during the 18-
month LTE period. LDAS Low disease activity score, DAS disease
activity score, CRP C-reactive protein, LTE long-term extension
[Genovese MC, Becker JC, Schiff M et al. (2005). Abatacept for
rheumatoid arthritis refractory to tumor necrosis factor alpha inhibi-
tion. N Engl J Med 353:1114–1123. Copyright © 2005 Massachusetts
Medical Society. All rights reserved; Genovese MC, Schiff M, Luggen
M et al. (2007) Efficacy and safety of the selective co-stimulation
modulator abatacept following 2 years of treatment in patients with
rheumatoid arthritis and an inadequate response to anti-TNF therapy.
Ann Rheum Dis 67:547–554. Reproduced with permission from the
BMJ Publishing Group]
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patients receiving abatacept [29, 32], thereby enhancing the
patient’s ability to live a normal life.
Improvements in physical function were assessed in the
ATTAIN trial using the Health-Assessment Questionnaire
Disability Index (HAQ-DI). At baseline, patients exhibited
substantial impairment in physical function, with an average
HAQ-DI score of 1.8 across the treatment groups. In this
trial, a patient was considered a HAQ-DI responder if they
achieved an improvement of at least 0.3 units from baseline
(exceeding the 0.22 value that is considered clinically
meaningful [33]). After 6 months of treatment, 47.3% of
patients receiving abatacept had a clinically meaningful
improvement in their HAQ-DI score, whereas significantly
fewer placebo-treated patients (23.3%) had a similar
improvement ( p<0.001; Fig. 4a) [29]. The abatacept group
showed a significant improvement from baseline of
0.45 units in their HAQ-DI score after 6 months, compared
with an improvement of 0.11 units shown by the placebo
group ( p<0.001) [29]. The clinically meaningful improve-
ments seen at 6 months were maintained through 2 years
Fig. 4 ATTAIN phase III trial: physical function during the double-
blind and long-term extension periods [29, 30]. a The proportion of
patients achieving clinically meaningful HAQ-DI responses at
6 months (double-blind period. b The proportion of patients achieving
clinically meaningful HAQ-DI responses through 2 years using post
hoc as-observed analysis of patients originally randomized to
abatacept at the beginning of the 6-month double-blind period and
continued receiving abatacept during the 18-month LTE period. A
clinically meaningful improvement from baseline was considered to be
≥0.3 units in the HAQ-DI. Bars on the 2-year data represent 95% CI.
*HAQ-DI responses are based on the ITT population for patients
originally randomized to receive abatacept, with data available at the
visit of interest (post hoc as-observed analysis). HAQ-DI Health
Assessment Questionnaire Disability Index, ITT intent to treat, LTE
long-term extension [Genovese MC, Becker JC, Schiff M et al. (2005).
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor
alpha inhibition. N Engl J Med 353:1114–1123. Copyright © 2005
Massachusetts Medical Society. All rights reserved; Genovese MC,
Schiff M, Luggen M et al. (2007) Efficacy and safety of the selective
co-stimulation modulator abatacept following 2 years of treatment in
patients with rheumatoid arthritis and an inadequate response to anti-
TNF therapy. Ann Rheum Dis 67:547–554. Reproduced with permis-
sion from the BMJ Publishing Group]
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(Fig. 4b); approximately two-thirds of patients originally
randomized to receive abatacept experienced an improve-
ment in physical function at 2 years using the post hoc
as-observed analyses.
Although improvement in physical function is salient,
other aspects of patient health, including mental state and
overall QoL are becoming increasingly important when
measuring the efficacy of a therapy for RA [5, 33, 34].
Improvements in health-related QoL were evaluated in the
ATTAIN trial using the Medical Outcomes Study Short
Form-36 (SF-36). The SF-36 consists of 36 items, 35 of
which evaluate eight dimensions of health, including four
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physical (physical functioning, role–physical, bodily pain,
general health) and four mental subscales (vitality, social
functioning, role–emotional, mental health), as well as
overall summary scores for the physical and mental compo-
nents. During the double-blind period, patients receiving
abatacept showed greater improvements than placebo-treated
patients in the change from baseline in the scores for all eight
physical and mental subscales of the SF-36 and both
component summary scores (Fig. 5a) [29] and these were
maintained or increased through 2 years (Fig. 5b) [30]. For
the mental component summary of the SF-36 analyses, the
mean change from baseline (± standard deviation) was 5.4±
11.7 units after 6 months of abatacept therapy compared
with 1.7±0.2 units for the placebo group (p=0.0025) [5]. At
2 years, the greatest improvements were observed in the
physical component subscales including bodily pain and
role–physical [30]. The mean improvements from baseline
in the physical and mental component summaries (PCS and
MCS, respectively) at 6 months and 2 years for patients
originally randomized to receive abatacept were 38.1 and
48.3, respectively, which are 10.3 and 6.2 point improve-
ments from baseline (Fig. 5c).
Patients were also asked to monitor the degree of fatigue
they experienced using a visual analogue scale (VAS) ranging
from no fatigue at score ‘0’ to extreme fatigue at score ‘100’.
The abatacept-treated group improved significantly more
than the placebo-treated group at 6 months, with the mean
fatigue VAS score decreasing by 22.1±28.6 in the abatacept
group compared with a decrease of 5.3±27.4 for the placebo
group ( p<0.0001) [5]. This significant and clinically
meaningful improvement in physical and mental health,
including fatigue, is important, particularly in this popula-
tion of patients who have severe disease and limited
treatment options.
Safety of abatacept in the ATTAIN trial
During the double-blind period, the overall frequencies
of AEs and serious AEs (SAEs) were not significantly
different in abatacept- and placebo-treated patients. A total
of 79.5% of patients receiving abatacept and 71.4% of
patients receiving placebo reported AEs during the double-
blind period ( p=0.08); SAEs were also reported with
similar frequency in the abatacept (10.5%) and placebo
(11.3%) groups ( p=0.81) [29]. Similar types of AEs, in-
cluding infusion-related events, were also reported during
the LTE period. Incidence rates of SAEs were consistent for
the double-blind and cumulative (double-blind plus LTE)
periods, with rates of 25.6 and 23.4/100 patient-years,
respectively. The most frequent SAEs for the cumulative
period were reported to be infestations and infections, and
malignancies. A total of 11 malignancies were reported
during the cumulative period, including non-melanomatous
skin cancers, basal cell carcinoma (n=3 patients) and
squamous cell carcinoma (n=2 patients). During the
double-blind period, the overall frequency of discontinua-
tion due to AEs or SAEs was low and was similar in both
groups (discontinuations due to AEs for the abatacept group
versus placebo group: nine patients [3.5%] versus five
patients [3.8%], respectively; discontinuations due to SAEs
for abatacept group versus placebo group: seven patients
[2.7%] versus two patients [1.5%] placebo group, respec-
tively; p=0.89). During the cumulative period, a total of 25
patients discontinued due to AEs and 18 patients discon-
tinued due to SAEs.
There was no significant difference in the frequency of
infections between the abatacept and placebo groups during
the double-blind period (37.6% versus 32.3%, respectively;
p=0.30). Generally, infections were reported as mild to
moderate in intensity, with nasopharyngitis, sinusitis, upper
respiratory tract infections, and bronchitis being the most
frequent, and no unusual or opportunistic infections were
observed. For the double-blind period, discontinuations due
to infection were 0.8% in the abatacept group compared
with 1.5% in the placebo group ( p=0.61). During the
cumulative period, overall infections and serious infections
occurred in 234 and 25 patients, with incidence rates of
89.4 and 5.0/100 patients–years, respectively. These rates
were similar to those reported for the double-blind period
Fig. 5 ATTAIN phase III trial: health-related quality of life during the
double-blind and long-term extension period [29, 30]. a The effect of
abatacept and placebo on the mean change from baseline in the
individual subscales of the SF-36 at 6 months (double-blind period). For
the double-blind period, two patients in the abatacept group were
excluded from the efficacy analysis because of a protocol violation. b
The effect of abatacept on the mean change from baseline in the
individual subscales of the SF-36 at 2 years using post hoc as-observed
analysis of patients originally randomized to abatacept at the beginning
of the 6-month double-blind period and continued receiving abatacept
during the 18-month LTE period [35]. Scores can range from 0 to 100,
with higher scores indicating a better quality of life. An improvement of
3 units is considered clinically meaningful [36], as indicated by the
dotted line. cMean change from baseline in the PCS and MCS scores at
6 months and 2 years in all patients who entered the LTE period.
Patients who received placebo plus DMARDs during the initial double-
blind period were reallocated to abatacept plus DMARDs at the start of
the LTE. Both double-blind (day 1 to month 6) and LTE (month 6 to
month 24) data are represented. SF-36 Short form-36, LTE long-term
extension, PCS physical component summary, MCS mental component
summary, DMARD disease-modifying anti-rheumatic drug [Genovese
MC, Becker JC, Schiff M et al. (2005). Abatacept for rheumatoid
arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J
Med 353:1114–1123. Copyright © 2005 Massachusetts Medical
Society. All rights reserved; Genovese MC, Schiff M, Luggen M et al.
(2007) Efficacy and safety of the selective co-stimulation modulator
abatacept following 2 years of treatment in patients with rheumatoid
arthritis and an inadequate response to anti-TNF therapy. Ann Rheum
Dis 67:547–554. Reproduced with permission from the BMJ Publishing
Group]
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(108.8 and 5.3/100 patients–years, respectively). For the
cumulative period, discontinuations due to infections
occurred in five patients, three of which had serious
infections (pneumonia, streptococcal sepsis, and subacute
endocarditis).
Overall, the 30-min intravenous abatacept infusion was
well tolerated by patients in this trial [29] and did not require
premedication [37]. The incidence of infusion reactions was
low, reported by only 5% of abatacept-treated patients
compared with 3% of the placebo-treated patients ( p=
0.35), and no severe or very severe reactions were observed
in either group during the double-blind period. The most
common infusion events experienced were dizziness
(reported by 1.6% of the abatacept-treated patients and
0.0% of placebo-treated patients; p=0.30) and headache
(reported by 1.2% of abatacept-treated patients and 0.8% of
placebo-treated patients; p=1.0). The incidence of infusion
events during the cumulative period was similar to those
reported during the double-blind period.
In other randomized clinical trials, including the AIM
(Abatacept in Inadequate responders to Methotrexate) trial,
the use of abatacept earlier in the treatment paradigm in
patients with an inadequate response to MTX has been
evaluated [37, 38]. Abatacept demonstrated favorable
efficacy in this trial, including inhibition of radiographic
progression through 2 years [39], which was not measured
in the ATTAIN trial, with an acceptable safety profile.
Abatacept is not indicated for use in this patient population
in the EU, but it has been approved in other countries,
including the USA, for the treatment of patients with
moderate to severe RA who have shown an inadequate
response to non-biologic DMARDs.
Conclusions
The ultimate goal of treating autoimmune diseases, such as
RA, should be to suppress the aberrant immune response in
a specific and long-term manner without compromising
normal immunity. Although many patients with RA are
successfully treated with traditional, non-biologic DMARDs,
until recently there has been a dearth of treatment options
available to patients who have failed these agents. The advent
of TNF-α antagonists has provided hope to these patients;
however, some patients also fail to respond to these therapies,
lose their response over time, or suffer intolerable side effects
[2, 14, 18]. Hence, there is a need for treatments with distinct
MoAs for use in this refractory population.
Selective T-cell co-stimulation modulation with abatacept
offers a potentially valuable therapeutic option for patients
with RAwho are refractory to TNF-α antagonist therapy and
have progressed through the treatment paradigm and are
more likely to have severe disease.
Abatacept has been shown to be efficacious in patients
with moderate to severely active RAwho had failed at least
3 months of TNF-α antagonist therapy in the ATTAIN trial.
The data presented here from the ATTAIN trial demonstrates
that abatacept provides significant improvements in the signs
and symptoms of RA, as well as improves QoL outcomes,
including fatigue, mental health, and physical disability for
up to 2 years [5, 29, 30, 32]. Data from this trial also
demonstrate that abatacept has an acceptable safety and
tolerability profile with a low (and not dissimilar to placebo)
frequency of infusion reactions and serious infections.
Although longer-term data on efficacy and safety are
needed to further validate T-cell co-stimulation modulation
as a therapeutic approach for RA, abatacept clearly con-
tributes to bridging the unmet need for managing disease
progression in patients for whom TNF-α antagonist therapy
has failed.
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